false
English
Catalog
2024 World Conference on Lung Cancer (WCLC) - ePos ...
EP.12A.38 Durable Response to Savolitinib in Advan ...
EP.12A.38 Durable Response to Savolitinib in Advanced EGFR-WT NSCLC with MET Amplification: Case Series
Back to course
Pdf Summary
In a case series examining the effects of Savolitinib on advanced non-small cell lung cancer (NSCLC) with MET amplification, promising results were observed. Savolitinib, a highly selective MET tyrosine kinase inhibitor, has already been approved in China for treating advanced NSCLC with MET 14 exon skipping mutation after chemotherapy failure. This study aimed to evaluate its efficacy and safety when used as a first-line or salvage treatment in NSCLC patients with MET amplification but without EGFR, ALK, or ROS1 mutations.<br /><br />The study consisted of four patients with stage IVb EGFR wild-type NSCLC identified with MET amplification. Two of them started Savolitinib as first-line therapy, while the others received it post failure of previous treatments, including entrectinib, nab-paclitaxel, and carboplatin.<br /><br />Remarkably, all patients achieved a partial response (PR) within a month of starting Savolitinib, with three maintaining PR until the data cutoff and one experiencing disease progression after seven months. Molecular analysis identified various concurrent mutations and alterations like TP53, ARID1A, and others in patients, though these did not hinder the efficacy of Savolitinib.<br /><br />Regarding safety, three patients tolerated the treatment well with no adverse events, while one developed interstitial pneumonia, managed with steroids.<br /><br />The findings suggest Savolitinib induces a rapid and durable response in NSCLC patients with MET amplification, irrespective of treatment line and presence of other mutations. While the safety profile shows acceptable tolerability, confirming these results in larger cohorts with extended follow-ups is required. This study underscores the potential of Savolitinib as an effective treatment option for MET-amplified NSCLC.
Asset Subtitle
Jianwei Liu
Meta Tag
Speaker
Jianwei Liu
Topic
Metastatic Non-small Cell Lung Cancer – Targeted Therapy
Keywords
Savolitinib
non-small cell lung cancer
NSCLC
MET amplification
tyrosine kinase inhibitor
EGFR wild-type
partial response
interstitial pneumonia
treatment efficacy
safety profile
×
Please select your language
1
English
5
普通话
11
Dutch